|Title: ||Adherence to oral anticancer drugs (OAD) in patients with metastatic renal cancer (mRCC): interim results of the prospective observational multicenter IPSOC study (Investigating Patient Satisfaction with Oral antiCancer Treatment)|
|Authors: ||Wolter, Pascal|
De Coster, Sandra
Foulon, Veerle #
|Issue Date: ||2012 |
|Conference: ||ESPACOMP date:25-27 October 2012|
|Abstract: ||Objectives: To investigate the prevalence and severity of non-adherence to OAD in mRCC and to identify
factors predictive of non-adherence.
Methods: Prospective observational multicenter trial performed at 11 Belgian hospitals. All patients with
mRCC starting OADs are eligible for the study. Patients are contacted by phone at baseline and at 1, 3, 6
and 12 months. At each contact, patients are asked to complete questionnaires investigating 1) medication
adherence (MMAS), 2) patient satisfaction with treatment (CTSQ) and with treatment education (PS-CaTE),
3) extent of information desire (EID) and 4) quality of life (FACT-G). Adherence is measured with MEMS®
Results: Between 02/2011 and 05/2012, 80 patients with a median age of 65 years have participated in the
study. With a median follow-up of 150 days (range 3 - 465) 87% of patients claimed to be fully adherent
(based on MMAS and CTSQ data). Ten patients indicated to have missed at least one dose, for which the
most important reasons were forgetting (38% of cases) and side effects (31%). Based on MEMS® data,
mean adherence, defined as the percentage of days with at least the prescribed number of dosage taken,
was 97.95%. Interestingly, the prescribed regimen was changed or interrupted by the treating oncologist in
36% of cases.
Median EID and FACT-G scores were significantly higher at baseline compared to 1 month of treatment
(p<0,05). The mean score for the CTSQ subdomain ?satisfaction with treatment? was higher at month 3
compared to month 1 (p<0,05) while the mean score for ?feelings about side effects? decreased significantly
between month 1 and 3.
Conclusions: The IPSOC study, the first to examine adherence to OAD among mRCC patients, shows that
mRCC patients are almost fully adherent to treatment recommendations. This seems to be in contrast to
adherence data for other, long-lasting, anti-cancer treatments.
|Publication status: ||published|
|KU Leuven publication type: ||IMa|
|Appears in Collections:||Research Centre for Pharmaceutical Care and Pharmaco-economics (-)|
Laboratory of Experimental Oncology